Last reviewed · How we verify
Tillotts Pharma AG — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
5 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mesalamin | Mesalamin | marketed | Other | |||
| TP05 | TP05 | phase 3 | Phosphodiesterase 4 (PDE4) inhibitor | PDE4 | Dermatology |
Therapeutic area mix
- Dermatology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Alfasigma S.p.A. · 1 shared drug class
- Almirall, S.A. · 1 shared drug class
- Arcutis Biotherapeutics, Inc. · 1 shared drug class
- Galderma R&D · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- LEO Pharma · 1 shared drug class
- Mallinckrodt · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Tillotts Pharma AG:
- Tillotts Pharma AG pipeline updates — RSS
- Tillotts Pharma AG pipeline updates — Atom
- Tillotts Pharma AG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Tillotts Pharma AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tillotts-pharma-ag. Accessed 2026-06-10.